ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol

Human epidermal growth factor receptor 2 (HER2) subtype of breast cancer is aggressive, leading to a poor outcome. Targeted therapy with trastuzumab has been shown to be effective in the treatment of HER2-positive breast cancer. Cardiotoxicity is a specific adverse effect associated with trastuzumab...

Full description

Saved in:
Bibliographic Details
Published in:JCO Glob Oncol
Main Authors: Ntekim, Atara I., Ibraheem, Abiola, Sofoluwe, Adenike A., Kotila, Olayinka, Babalola, Chinedum, Karrison, Theodore, Olopade, Christopher O.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2020
Subjects:
Review Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392776/
https://ncbi.nlm.nih.gov/pubmed/32628583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/GO.20.00043
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items